ERBB2 and breast carcinoma: The MET-PI3K/Akt axis is involved in breast cancer resistance to doxorubicin (Kyeong-Ah et al., 2015) and trastuzumab resistance in HER2 overexpressing breast cancer cells (Shattuck et al., 2008).